<DOC>
	<DOCNO>NCT00006206</DOCNO>
	<brief_summary>Combine multicenter , randomize clinical trial evaluate combination three intervention treat alcohol dependence . The goal determine whether improvement treatment outcomes achieve various combination drug behavioral intervention . Two intervention consist pharmacological treatment naltrexone ( Revia ) acamprosate ( Campral ) . The third intervention multicomponent behavioral therapy include component motivational enhancement therapy , cognitive behavioral therapy , referral self-help group , include AA . All three intervention include component support compliance medication reduction drinking .</brief_summary>
	<brief_title>COMBINE ( Acamprosate/Naltrexone )</brief_title>
	<detailed_description />
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<mesh_term>Acamprosate</mesh_term>
	<criteria>Inclusion criterion The follow inclusion criterion meet : 1 . Male female outpatient &gt; 18 year age . 2 . Participants current DSMIV diagnosis alcohol dependence . 3 . Participants sign witness informed consent . 4 . Participants must drink minimum &gt; 14 drink ( female ) &gt; 21 drink ( male ) average per week consecutive 30day period 90day period prior initiation abstinence , two day heavy drinking ( defined 4 drink female 5 drink male ) 90day period prior initiation abstinence . 5 . Participants must minimum 4 consecutive day ( 96 hour ) abstinence CIWA &lt; 8 prior randomization . 6 . Participants abstinent maximum 21 day prior randomization . 7 . Participants 21 consecutive day plan absence 16 week active treatment period . 8 . Participants able identify least one `` locator '' person assist track participant followup assessment . 9 . Participants able speak understand English . Exclusion criteria The following exclusion criterion rule participant : 1 . Participants meet current DSMIV criterion bipolar disorder , schizophrenia , bulimia/anorexia , dementia , psychological disorder require medication . 2 . Participants require concomitant therapy medication pose safety issue ( see Appendix B ) . 3 . Participants current diagnosis dependence drug except nicotine , cannabis , alcohol , habitual caffeine use . If positive urine screen participant retested ( metabolic ) interval appropriate drug . If second urine drug screen positive person exclude . 4 . Participants meet DSMIV criterion opiate dependence abuse within past 6 month , chronic treatment opiatecontaining medication previous month , urine positive opioids . 5 . Participants significant medical disorder increase potential risk study treatment interfere study participation , participant sensitivity study medication relate drug evidence adverse drug experience , especially opiatecontaining analgesic , opioid antagonist , acamprosate . 6 . Participants abnormal AST ALT ( 3 time upper limit normal range ( ULN ) ) elevate bilirubin ( 10 % ULN ) . Tests may repeat initial result range . 7 . Participants pregnant nursing infant ( ) , woman childbearing potential use contraceptive method judge investigator effective . 8 . Participants intend engage additional formal treatment alcoholrelated problem , intend continue current treatment alcoholrelated problem active treatment period . Selfhelp treatment consider formal treatment . 9 . Participants seven day inpatient treatment substance use disorder 30 day previous randomization . 10 . Participants prior use study medication ( ) last 30 day . Any question concern interpretation application inclusion/exclusion criterion refer medical expert Coordinating Center . If unavailable , question refer Chairperson Treatment Subcommittee .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2007</verification_date>
</DOC>